Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial

Bernardo M, Dodd S, Gama CS, Copolov DL, Dean O, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI, Berk M. Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial.

Objective: To evaluate the effect of N-acetylcysteine (NAC) on substance use in a double-blind, placebo-controlled trial of NAC in bipolar disorder. It is hypothesised that NAC will be superior to placebo for reducing scores on the Clinical Global Impressions scale for Substance Use (CGI-SU).
Methods: Participants were randomised to a 6-months of treatment with 2 g/day NAC (n = 38) or placebo (n = 37). Substance use was assessed at baseline using a Habits instrument. Change in substance use was assessed at regular study visits using the CGI-SU.
Results: Among the 75 participants 78.7% drank alcohol (any frequency), 45.3% smoked tobacco and 92% consumed caffeine. Other substances were used by fewer than six participants. Caffeine use was significantly lower for NAC-treated participants compared to placebo at week 2 of treatment but not at other study visits.
Conclusions: NAC appeared to have little effect on the participants who were using substances. A larger study on a substance-using population will be necessary to determine if NAC may be a useful treatment for substance use.

Michelle Bernardo[1], Seetal Dodd[1], Clarissa S. Gama[4], David L Copolov[3,5], Olivia Dean[1,3], Kristy Kohlmann[1,3], Susan Jeavons[3], Ian Schapkaitz[3], Murray Anderson-Hunt[3], Ashley I Bush[3] Michael Berk[1,2,3]

[1] The University of Melbourne, Department of Clinical and Biomedical Sciences: Barwon Health, Geelong, Australia; [2] Orygen Research Centre, Parkville, Australia; [3] Mental Health Research Institute, Parkville, Australia; [4] Laboratório de Psiquiatria Molecular, Centro de Pesquisas, Hospital de Clínicas de Porto Alegre, Brazil; [5] Monash University, Clayton, Australia

Seetal Dodd, The University of Melbourne, Department of Clinical and Biomedical Sciences: Barwon Health, PO Box 281, Geelong 3220, Australia.
Tel: +6135226/7666;
Fax: +61352465165;
E-mail: seetald@barwonhealth.org.au

Introduction

Bipolar disorder is a chronic and devastating major mental illness that may affect up to 5% of the population (1). Substance abuse or dependence is highly prevalent in bipolar disorder (2) and is associated with an increased rate of relapse and number of hospitalisations (3–5).

The role of oxidative biology in substance use disorders in not fully understood, but some agents such as amphetamines robustly increase oxidative stress, and have been used as animal models of oxidative stress in psychiatric disorders (6). In addition, there has been strong evidence that oxygen-free radicals may play an important role in the pathophysiology of major mental illnesses like bipolar disorder and schizophrenia (7).

Much of the focus on antioxidant defence mechanism has been on the key scavenging antioxidant enzymes; superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) that are altered in bipolar disorder and schizophrenia (7). GPx catalyses the scavenging of hydrogen peroxide and other radicals by glutathione. Decreased peripheral GPx activity has been described in bipolar disorder, which normalised with treatment (8). Several plasma lipid peroxides like malondialdehyde (MDA) and thiobarbituric acid reactive substances (TBARS) have recently been studied in bipolar disorder (9–11) and schizophrenia (12–15), providing evidence of increased levels of lipid peroxidation products in the plasma of people with bipolar disorder and schizophrenia.

Glutamate is thought to have a critical role in the neurobiology of addiction (16). In addition, magnetic resonance spectroscopy studies of patients with bipolar disorder have found an increase in

the glutamine/glutamate combined signal in frontal lobes, basal ganglia and left dorso-lateral prefrontal cortex (17). The nucleus accumbens (NA) is a key neural substrate underpinning drug reward. In the NA, basal levels of extracellular glutamate are maintained primarily by the exchange of extracellular cysteine for intracellular glutamate, through the cysteine glutamate exchange system. This exchange system is ubiquitous in the brain, and also has a role in protecting against oxidative stress by providing cysteine, the rate-limiting factor, for glutathione synthesis. Glutathione is the brain's principal oxidative free radical scavenger and substance use has been associated with increased oxidative stress (18) In addiction, there is a persistent reduction in cystine–glutamate exchange in the NA, which may contribute to pathological glutamate signalling. Drug withdrawal is further associated with reduced glutamate, as a result of decreasing the exchange of extracellular cysteine for intracellular glutamate (19). The effects of glutamate in the NA are mediated by group II metabotropic glutamate autoreceptors.

N-acetylcysteine (NAC) increases extracellular levels of glutamate and thereby stimulates group II metabotropic glutamate receptors (20). Increasing glutamate in the NA blocks craving and the re-instatement of compulsive drug-seeking behaviours. In a rat model of cocaine addiction, McFarland et al. (21) reported that drug-seeking behaviour was mediated by prefrontal glutamate release into the NA. Concordant with this, NAC prevented escalation of drug intake and behavioural sensitisation in an animal model of cocaine addiction (22). Baker et al. (19) have also shown that NAC prevented re-instatement of drug-seeking behaviour through stimulating cysteine glutamate exchange, in a cocaine model of addiction. NAC also blocks heroin-induced re-instatement behaviour and cue responsivity, suggesting that this mechanism plays an important role in the reward circuitry in addictive states (23). Thus, NAC treatment may be able to restore extracellular glutamate in NA, which may inhibit compulsive behaviours and reduce cravings (24). The ability of NAC to increase the activity of the cysteine glutamate exchange system, and thus increase glutamate through restoring exchanger activity is mediated through metabotropic glutamate receptors, which regulate the release of vesicular dopamine and glutamate (20). Dopamine is also a key component in reward and re-instatement behaviour (19), and might be one key pathway whereby NAC might be active in the treatment of addiction.

Brain glutathione (GSH) is readily replenished by elevating plasma levels of its rate-limiting precursor, cysteine. Oral NAC is bioavailable, and is de-acetylated in the liver (25,26), and is a viable method for replenishing brain GSH. Animal models have confirmed that administration of NAC protects against GSH depletion (27). A neuroprotective effect of NAC has been suggested by protection in a variety of neurodegenerative disease models (28–34). In randomised, double-blind, placebo-controlled clinical trials, NAC adjunctive to treatment as usual has been demonstrated to be efficacious for the treatment of schizophrenia (35) and bipolar disorder (36). Substance use is an important comorbidity in bipolar disorder. Oxidative stress has been found in both bipolar disorder and addiction, suggesting that NAC may be worth investigating for the treatment of both of these disorders.

In this study, data on substance use were collected from a 24-week, double-blind, randomised, placebo-controlled efficacy trial of NAC in bipolar disorder (36).

Material and Methods

Full methodological details of the primary trial are published elsewhere (36). Participants had a diagnosis of bipolar disorder (I or II) with at least one documented episode of illness in the past 6 months. Exclusion criteria were an episode of illness in the previous 1 month, pregnancy or lactation, or a relevant medical disorder. Eligible participants were assigned randomly and consecutively to either two 500 mg capsules b.i.d. (twice daily) to a total of 2 g daily of NAC ($n = 38$) or placebo ($n = 37$) in a double-blind fashion for 24 weeks. Participants were assessed by a trial clinician at baseline (week 0), and weeks 2, 4, 8, 12, 16, 20 and 24, and for a final visit after discontinuation and washout at week 28.

Withdrawal from the trial occurred if participants ceased taking their trial medication for 7 consecutive days, ceased effective contraception or became pregnant. Dose changes to existing medications (either increases or decreases in dose), or addition or removal of an agent were accepted and participants were allowed to continue with the trial. Participants were withdrawn from the study if they decided to withdraw their consent.

Information regarding the participant's initial substance use was obtained. These data were collected at baseline prior to dispensing the trial medication to measure substance use. The questionnaire used provided a quantified measure of ethanol (alcohol), caffeine, nicotine (tobacco), alpha-methyl-phenethyl-amine (amphetamine), delta-9-tetrahydrocannabinol (marijuana), methylene-dioxy-meth-amphetamine (ecstasy), opiates and benzodiazepines and was used as a reference in determining whether the use of substances had increased or decreased.

The Clinical Global Impression – Substance Use (CGI-SU) (Appendix A), was a modification of the CGI (37), and was used to measure change in substance use during the trial. It was administered at all study visits after commencing treatment (weeks 2 to 28) by a trained clinician. The CGI-SU rates change from baseline in substance use for alcohol, tobacco, caffeine, cannabis and up to two 'other' substances. The CGI-SU asks participants to rate on a 7-point Likert scale their change in substance use for each substance, where 1 = don't use at all now, 2 = using much less, 3 = using slightly less, 4 = unchanged, 5 = using slightly more, 6 = using much more and 7 = using very much more.

Statistical analyses were performed using Minitab Statistical Package Release 14 and Statistical Package for the Social Sciences (SPSS) for windows version 14 software. A blinded code for NAC treatment and placebo was used during the analyses. Between-group comparisons were Student's t-test, for parametric data. Fisher's exact test was used to compare dichotomy variables between groups. A General Linear Model adjusted for treatment and pooled investigator was used to determine changes between treatment and placebo groups.

Between-group comparisons for age, gender and treatment sector (private or public) was conducted using data collected at baseline. Between-group comparisons for current mood status were conducted using Montgomery Åsberg Depression Rating Scale (MÅDRS) and Young Mania Rating Scale (YMRS). Data were collected at visit 2 (week 2), as visit 2 was the first occasion that the MÅDRS and YMRS scales were administered to study participants. Participants with an MÅDRS score of 10 or higher were classed as currently depressed and participants with a YMRS score of 12 or higher were classed as currently manic. These scores were used to determine a 'yes/no' classification for current depression or mania.

Substance use recorded from the Habits instrument (37) at baseline was also dichotomised into a 'yes/no' classification, where 0 = doesn't usually drink/smoke/use was classified as 'no'. The remaining 1–5 responses were classified as 'yes'. Similarly, scores for change in substance use measured using the CGI-SU were also dichotomised for statistical analysis: 1–4 = improvement or no change and 5–7 = slightly to very much worse.

This study protocol was approved, by the by, the Barwon Health Research and Ethics Advisory Committee and the Bendigo Health Care Group Human Research Ethics Committee. In accordance with the Declaration of Helsinki, all participants were advised about the procedure and they signed the informed consent prior to participation in the study.

Table 1. Participant characteristics at baseline

Variables	NAC ($n = 38$) n (%)	Placebo ($n = 37$) n (%)	Overall ($n = 75$) n (%)	P-value*
Age (SD), years	44.6 (11.2)	46.6 (13.8)	45.6 (12.5)	0.500
Gender				
Female	23 (60.5)	22 (59.5)	45 (60)	
Male	15 (39.5)	15 (40.5)	30 (40)	1.000
Treating sector				
Public	10 (26.3)	8 (21.6)	18 (24)	
Private	28 (73.7)	29 (78.4)	57 (76)	0.788
Current mood state				
Depressed (MÅDRS)				
No	16 (42.1)	18 (48.6)	34 (45.3)	
Yes	22 (57.9)	20 (51.4)	41 (54.7)	0.646
Manic (YMRS)				
No	35 (92.1)	33 (89.2)	68 (90.7)	
Yes	3 (7.9)	4 (10.8)	7 (9.3)	0.711
Baseline substance use				
Alcohol				
Doesn't drink	7 (18.4)	9 (24.3)	16 (21.3)	
Drinks (any frequency/amount)	31 (81.6)	28 (75.7)	59 (78.7)	0.583
Tobacco				
Doesn't smoke	23 (60.5)	18 (48.6)	41 (54.7)	
Smokes (any frequency)	15 (39.5)	19 (51.4)	34 (45.3)	0.357
Caffeine				
Doesn't drink	4 (10.5)	2 (5.4)	6 (8)	
Drinks (any frequency/amount)	34 (89.5)	35 (94.6)	69 (92)	0.674
Cannabis				
Doesn't use	34 (89.5)	35 (94.6)	69 (92)	
Uses (any frequency/amount)	4 (10.5)	2 (5.4)	6 (8)	0.674

*Continuous data analysed using the 2-sample t-test, categorical data analysed using the Fisher's exact test. Data are given as mean (standard deviation) or number (percentage).

Results

Comparisons at the baseline visit between NAC- and placebo-treated participants for age, gender, treating sector and substance use or at visit 2 for mood state, suggested that the two groups were not significantly different (Table 1). Fifty-eight (77.3%) participants completed the trial.

Comparisons for change in substance use between NAC- and placebo-treated participants was calculated for alcohol, caffeine and tobacco use only, as there were not enough participants who used other substances to permit statistical comparisons. No significant difference was observed between NAC- and placebo-treated participants for change from baseline in alcohol or tobacco at any of the study visits. A significant decrease (p < 0.05) in caffeine use was observed for NAC-treated participants, compared to placebo-treated participants, at study visit 2 (2 weeks); however, this difference did not remain statistically significant at any of the other study visits (Tables 2–4).

Table 2. Mean alcohol (observed cases) scores by NAC and placebo groups for each visit

Visits	N	NAC Mean (SD) Median (range)	LS mean* (95% CI)	N	Placebo Mean (SD) Median (range)	LS mean* (95% CI)	P-value *	P-value †
Week 2	32	3.47 (1.65) 4.00 (1.25−7.00)	3.47 (2.90, 4.04)	29	3.38 (1.55) 4.00 (2.00−7.00)	3.37 (2.77, 3.98)	0.819	0.631
Week 4	29	3.55 (1.55) 4.00 (2.50−7.00)	3.56 (2.94, 4.17)	28	3.54 (1.62) 4.00 (3.00−7.00)	3.55 (2.94, 4.17)	0.999	0.730
Week 8	24	3.50 (1.72) 4.00 (1.25−7.00)	3.50 (2.79, 4.21)	29	3.80 (1.74) 4.00 (2.50−7.00)	3.76 (3.10, 4.41)	0.596	0.581
Week 12	24	3.42 (1.56) 4.00 (3.00−7.00)	3.40 (2.75, 4.05)	24	3.42 (1.59) 4.00 (1.50−6.00)	3.42 (2.77, 4.07)	0.972	0.689
Week 16	23	3.61 (1.50) 4.00 (3.00−7.00)	3.62 (2.99, 4.24)	21	3.48 (1.44) 4.00 (2.50−5.00)	3.47 (2.82, 4.12)	0.747	0.950
Week 20	21	2.95 (1.72) 4.00 (1.00−7.00)	2.95 (2.24, 3.67)	22	3.68 (1.49) 4.00 (2.75−7.00)	3.68 (2.98, 4.38)	0.149	0.106
Week 24	20	3.35 (1.35) 4.00 (2.25−5.00)	3.35 (2.60, 4.10)	22	3.55 (1.87) 4.00 (1.75−7.00)	3.55 (2.83, 4.26)	0.704	0.760
Week 28	23	3.17 (1.70) 4.00 (1.00−7.00)	3.22 (2.60, 3.85)	27	3.41 (1.34) 4.00 (3.00−6.00)	3.37 (2.79, 3.94)	0.736	0.687

SD, standard deviation; LS mean, least squares mean; CI, confidence interval.
*General linear model (GLM) adjusting for treatment and pooled investigator,
†Wilcoxon rank-sum test.

Table 3. Mean smoking (OC) scores by NAC and placebo groups for each visit

Visits	N	NAC Mean (SD) Median (Range)	LS Mean* (95% CI)	N	Placebo Mean (SD) Median (Range)	LS Mean* (95% CI)	P-value*	P-value †
Week 2	16	4.19 (1.22) 4.00 (2.00−7.00)	4.19 (3.51, 4.87)	18	3.28 (1.41) 4.00 (1.00−5.00)	3.31 (2.66, 3.96)	0.067	0.064
Week 4	15	3.73 (1.28) 4.00 (1.00−6.00)	3.74 (2.95, 4.52)	18	3.28 (1.60) 4.00 (1.00−6.00)	3.29 (2.56, 4.02)	0.399	0.450
Week 8	12	3.92 (1.08) 4.00 (1.00−5.00)	3.95 (3.10, 4.80)	18	3.22 (1.59) 4.00 (1.00−6.00)	3.16 (2.44, 3.87)	0.159	0.192
Week 12	10	3.70 (1.06) 4.00 (1.00−5.00)	3.68 (2.90, 4.46)	14	3.43 (1.22) 4.00 (1.00−5.00)	3.44 (2.78, 4.10)	0.640	0.500
Week 16	10	3.40 (1.35) 4.00 (1.00−5.00)	3.48 (2.61, 4.34)	12	3.33 (1.30) 4.00 (1.00−5.00)	3.27 (2.48, 4.06)	0.718	0.911
Week 20	9	3.44 (1.51) 4.00 (1.00−5.00)	3.46 (2.46, 4.46)	12	3.58 (1.31) 4.00 (1.00−5.00)	3.58 (2.72, 4.45)	0.850	0.938
Week 24	9	4.00 (1.32) 4.00 (1.00−6.00)	3.96 (2.90, 5.03)	11	3.36 (1.63) 4.00 (1.00−5.00)	3.39 (2.43, 4.35)	0.412	0.512
Week 28	10	4.20 (1.32) 4.00 (1.00−6.00)	4.18 (3.03, 5.33)	16	3.94 (1.91) 4.00 (1.00−7.00)	3.95 (3.04, 4.86)	0.749	0.785

SD, standard deviation; LS mean, least squares mean; CI, confidence interval.
*General linear model (GLM) adjusting for treatment and pooled investigator,
†Wilcoxon rank-sum test.

Discussion

This study provides negligible evidence to suggest that NAC may impact on substance use. NAC was superior to placebo for reducing caffeine use, but not for other substances, and the benefit was only observed at week 2 of treatment. The reduction in caffeine use may be mediated through a shared mechanism of drug re-instatement, mediated through glutamate or through the effects of glutathione and oxidative biology. These results need to be replicated in larger samples, with additional studies to investigate the mediating pathways.

The CGI-SU scale proved to be a useful and an easy-to-administer scale, which could easily be added as an outcome measure for inclusion in a clinical trial.

The principal limitation of this report is that the clinical cohort was selected on the basis of its meeting the criteria for bipolar disorder, not concomitant substance use, and hence the trial was powered for clinical parameters. The rates of substance use in

Table 4. Mean caffeine (observed cases) scores by NAC and placebo groups for each visit

Visits	N	NAC Mean (SD) Median (range)	LS mean* (95% CI)	N	Placebo Mean (SD) Median (range)	LS Mean* (95% CI)	P-value*	P-value †
Week 2	35	3.57 (1.01) 4.00 (1.00−5.00)	3.58 (3.29, 3.88)	35	4.00 (0.73) 4.00 (1.00−5.00)	4.02 (3.72, 4.32)	0.041*	0.037*
Week 4	32	3.63 (0.98) 4.00 (1.00−5.00)	3.64 (3.33, 3.94)	34	3.79 (0.73) 4.00 (2.00−6.00)	3.81 (3.52, 4.11)	0.414	0.610
Week 8	27	3.59 (1.12) 4.00 (1.00−5.00)	3.55 (3.20, 3.90)	34	3.88 (0.77) 4.00 (2.00−6.00)	3.92 (3.61, 4.24)	0.120	0.535
Week 12	24	3.75 (1.15) 4.00 (1.00−6.00)	3.72 (3.31, 4.14)	28	3.82 (0.91) 4.00 (2.00−6.00)	3.83 (3.45, 4.22)	0.690	0.984
Week 16	25	3.60 (1.26) 4.00 (1.00−6.00)	3.60 (3.16, 4.04)	25	3.96 (0.89) 4.00 (2.00−6.00)	3.96 (3.52, 4.40)	0.253	0.345
Week 20	22	3.68 (1.13) 4.00 (1.00−5.00)	3.69 (3.28, 4.10)	25	3.72 (0.74) 4.00 (2.00−5.00)	3.72 (3.34, 4.11)	0.901	0.718
Week 24	21	4.10 (0.89) 4.00 (2.00−7.00)	4.10 (3.68, 4.52)	25	3.84 (0.99) 4.00 (2.00−7.00)	3.84 (3.46, 4.23)	0.371	0.233
Week 28	25	3.72 (0.98) 4.00 (1.00−5.00)	3.72 (3.30, 4.14)	31	3.58 (1.09) 4.00 (1.00−6.00)	3.57 (3.20, 3.95)	0.615	0.414

SD, standard deviation; LS mean, least squares mean; CI = confidence interval. *$P < 0.05$.
*General linear model (GLM) adjusting for treatment and pooled investigator,
†Wilcoxon rank-sum test.

the cohort were low, which did not lend the statistical power to detect clear between-group differences. A larger sample size would be necessary to increase the statistical power. The fact that the impact on substance use was not a primary outcome of the trial might serve to reduce clinician or subject expectations and hence bias the results.

The clinical utility of NAC as a treatment for substance use is still to be fully defined. Further studies will be required to determine if NAC can be a useful treatment for substance use, either as monotherapy or as an adjunct to other therapies. It would be particularly useful to conduct a trial of NAC in a substance-using population.

Appendix A: Clinical Global Impression Scale for Substance Use

☐96 INFORMATION NOT OBTAINED

"Since the Beginning of NAC study 'How has your … (use of substances) … changed?'

A	beer, wine, spirits ('alcohol')	B	cigarettes, cigars, pipes ('smoking')
☐01	Do not drink at all now	☐01	Don't smoke at all now
☐02	Drink much less	☐02	Smoke much less
☐03	Drink slightly less	☐03	Smoke slightly less
☐04	Unchanged	☐04	Unchanged
☐05	Drink slightly more	☐05	Smoke slightly more
☐06	Drink much more	☐06	Smoke much more
☐07	Drink very much more	☐07	Smoke very much more
☐96	Didn't drink usually / Unknown	☐96	Didn't smoke usually / Unknown

.

Since Beginning of NAC study 'How has your … (use of these substances) … changed?'

C	coffee, tea, cola, etc ('caffeine')	D	marijuana
01	No 'caffeine' at all now	01	Don't smoke at all now
02	Drink much less	02	Smoke much less
03	Drink slightly less	03	Smoke slightly less
04	Unchanged	04	Unchanged
05	Drink slightly more	05	Smoke slightly more
06	Drink much more	06	Smoke much more
07	Drink very much more	07	Smoke very much more
96	Didn't drink usually / Unknown	96	Didn't smoke usually / Unknown

.

Since Beginning of NAC study 'How has your … (use of these substances) … changed?'

E	Other _____	F	Other _____
01	Don't use at all now	01	Don't use at all now
02	Use much less	02	Use much less
03	Use slightly less	03	Use slightly less
04	Unchanged	04	Unchanged
05	Use slightly more	05	Use slightly more
06	Use much more	06	Use much more
07	Use very much more	07	Use very much more
96	Didn't use usually / Unknown	96	Didn't use usually / Unknown

.

References

1. BERK M, DODD S, BERK L. The management of bipolar disorder in primary care: a review of existing and emerging therapies. Psychiatry Clin Neurosci 2005;**59**:229–239.
2. REGIER DA, FARMER ME, RAE DS et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;**264**:2511–2518.
3. GOLDBERG JF, GARNO JL, LEON AC, KOCSIS JH, PORTERA L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999;**60**:733–740.
4. DOSSING M, SONNE J. Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1993;**9**:441–449.
5. CASSIDY F, AHEARN EP, CARROLL BJ. Substance abuse in bipolar disorder. Bipolar Disord 2001;**3**:181–188.
6. CASTRO AA, MORETTI M, CASAGRANDE TS, MARTINELLO C, PETRONILHO F, STECKERT AV, GUERRINI R, CALO G, DAL PIZZOL F, QUEVEDO J, GAVIOLI EC. Neuropeptide S produces hyperlocomotion and prevents oxidative stress damage in the mouse brain: A comparative study with amphetamine and diazepam. Pharmacol Biochem Behav 2009;**91**:636–642.
7. REDDY RD, YAO JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996;**55**:33–43.
8. OZCAN ME, GULEC M, OZEROL E, POLAT R, AKYOL O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004;**19**:89–95.
9. MACHADO-VIEIRA R, ANDREAZZA AC, VIALE CI et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007;**421**:33–36.
10. ANDREAZZA AC, CASSINI C, ROSA AR et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007;**41**:523–529.
11. FREY BN, ANDREAZZA AC, KUNZ M et al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry 2007;**31**:283–285.
12. GRIGNON S, CHIANETTA JM. Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Prog Neuropsychopharmacol Biol Psychiatry 2007;**31**:365–369.
13. GAMA CS, BERK M, ANDREAZZA AC, KAPCZINSKI F, BELMONTE-DE-ABREU P. Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances

in chronically medicated schizophrenic patients: a positive correlation. Rev Bras Psiquiatr 2008;**30**:337–340.

14. GAMA CS, SALVADOR M, ANDREAZZA AC, KAPCZINSKI F, SILVA BELMONTE-DE-ABREU P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2006;**30**:512–515.

15. GAMA CS, SALVADOR M, ANDREAZZA AC et al. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci Lett 2008;**433**:270–273.

16. KALIVAS PW, O'BRIEN C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008;**33**:166–180.

17. STORK C, RENSHAW PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005;**10**:900–919.

18. WOZNIAK B, MUSIALKIEWICZ D, WOZNIAK A et al. Lack of changes in the concentration of thiobarbituric acid-reactive substances (TBARS) and in the activities of erythrocyte antioxidant enzymes in alcohol-dependent patients after detoxification. Med Sci Monit 2008;**14**:CR32–36.

19. BAKER DA, MCFARLAND K, LAKE RW et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 2003;**6**:743–749.

20. MORAN MM, MCFARLAND K, MELENDEZ RI, KALIVAS PW, SEAMANS JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005;**25**:6389–6393.

21. MCFARLAND K, LAPISH CC, KALIVAS PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 2003;**23**:3531–3537.

22. MADAYAG A, LOBNER D, KAU KS et al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. J Neurosci 2007;**27**:13968–13976.

23. ZHOU W, KALIVAS PW. N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking. Biol Psychiatry 2008;**63**:338–340.

24. GRANT JE, KIM SW, ODLAUG BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007;**62**:652–657.

25. BURGUNDER JM, VARRIALE A, LAUTERBURG BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989;**36**:127–131.

26. HOLDINESS MR. Clinical Pharmokinetics of N-acetylcysteine. Clin Pharmacokinet 1991;**20**:123–134.

27. DEAN O, VAN DEN BUUSE M, COPOLOV DL, BERK M, BUSH AI. N-acetylcysteine treatment inhibits depletion of brain glutathione levels in rats: Implications for schizophrenia. Int J Neuropsychopharmacol 2004;**7**:S262.

28. ANDREASSEN OA, DEDEOGLU A, KLIVENYI P, BEAL MF, BUSH AI. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. NeuroReport 2000;**11**:2491–2493.

29. LOUWERSE ES, WEVERLING GJ, BOSSUYT PM, MEYJES FE, DE JONG JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;**52**:559–564.

30. ROTHSTEIN JD, BRISTOL LA, HOSLER B, BROWN RH, Jr., KUNCL RW. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci U S A 1994;**91**:4155–4159.

31. KOPPAL T, DRAKE J, BUTTERFIELD DA. In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. Biochim Biophys Acta 1999;**1453**:407–411.

32. MAYER M, NOBLE M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci U S A 1994;**91**:7496–7500.

33. STAAL FJ, ANDERSON MT, HERZENBERG LA. Redox regulation of activation of NF-kappa B transcription factor complex: effects of N-acetylcysteine. Methods Enzymol 1995;**252**:168–174.

34. FERRARI G, YAN CY, GREENE LA. N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells. J Neurosci 1995;**15**:2857–2866.

35. BERK M, COPOLOV D, DEAN O et al. N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;**64**:361–368.

36. BERK M, COPOLOV DL, DEAN O et al. N-acetyl cysteine for depressive symptoms in bipolar disorder–a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;**64**:468–475.

37. GUY W. ECDEU assessment manual for psychopharmacology. Rockville: U.S. National Institute of Health, Psychopharmacology Research Branch, 1976.